Drugs / autologous melanoma lysate-pulsed autologous dendritic cell vaccine
autologous melanoma lysate-pulsed autologous dendritic cell vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01082198 | Oct 2002 → Apr 2010 | cutaneous melanoma | Maria Sklodowska-Curie National Research Institute of Oncology | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous melanoma lysate-pulsed autologous dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01082198 ↗ |
| Action | Deplete | “Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells.” NCT01082198 ↗ |
| Modality | Vaccine | “Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells.” NCT01082198 ↗ |
| Route | Subcutaneous | “autologous DCs pulsed with melanoma-associated antigen peptides, and autologous DCs pulsed with tumor lysates (if available), subcutaneously” NCT01082198 ↗ |